Compare AbCellera Biologics Inc (ABCL) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Novo Nordisk A/S — how do they compare? AbCellera Biologics Inc trades at $7.29 (market cap $2.35B), while Novo Nordisk A/S trades at $49.28 (market cap $220.20B). The key difference: Novo Nordisk A/S is far larger — about 93.7× AbCellera Biologics Inc's market cap, and Novo Nordisk A/S pays a 3.63% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | NVO | |
|---|---|---|
Market Cap | $2.35B | $220.20B |
Sector | Health | Health |
52-Week High | $8.12 | $71.70 |
52-Week Low | $2.78 | $35.29 |
Enterprise Value | $1.99B | $239.16B |
Dividend Yield | — | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Novo Nordisk (NVO) trades at $49.64, down 1.57% today, with strong technical momentum showing bullish moving average signals. The company demonstrates robust fundamentals with $309.1B revenue in 2025 and impressive profitability metrics including 37.2% net income margin and 71.4% ROE. Recent earnings beats and Medicare's GLP-1 coverage expansion for weight-loss drugs provide positive catalysts. Analyst consensus remains strongly bullish with 22 buy ratings versus only 3 sell recommendations.
NVO presents a compelling investment case with strong earnings growth, market leadership in GLP-1 therapies, and favorable valuation at 11.82 P/E. Key risks include intensifying competition in obesity drugs and potential pricing pressures. The stock's current technical setup near support at $49 suggests potential for rebound, supported by institutional confidence and positive business momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
